Submit Deal

CORMORANT ASSET MANAGEMENT

HQ - Boston

Summary

Cormorant Asset Management is a Boston-based investment manager with investment focus in both public and private market innovative companies in the biotechnology and life sciences marketplace.

Deals Overview

Total Deals54

Valued Deals53

Total Value£ 7.86 B

Avg. Deal Size£ 148 M

Market Context

Subsidiaries

HELIX ACQUISITION

1 transaction

Senior Management

Bihua Chen
CEO
Caleb Tripp
CFO
Raymond Kelleher
Managing Director

Sort

erasca

HQ - United States

Biotechnology

27 Apr 2020

Investment Date

£ 161 M

Deal Value

atea pharmaceuticals inc

HQ - United States

Pharmaceuticals

20 May 2020

Investment Date

£ 175 M

Deal Value

everest medicines ltd

HQ - China

Pharmaceuticals

5 Jun 2020

Investment Date

£ 245 M

Deal Value

greenlight biosciences inc

HQ - United States

Biotechnology

16 Jun 2020

Investment Date

£ 81 M

Deal Value

velosbio inc

HQ - United States

Biotechnology

8 Jul 2020

Investment Date

£ 105 M

Deal Value

element science inc

HQ - United States

Medical Equipment

3 Mar 2020

Investment Date

£ 114 M

Deal Value

bioatla

HQ - United States

Pharmaceuticals

17 Jul 2020

Investment Date

£ 55 M

Deal Value

vectivbio

HQ - Switzerland

Biotechnology

15 Oct 2020

Investment Date

£ 84 M

Deal Value

miragen therapeutics

HQ - United States

Biotechnology

28 Oct 2020

Investment Date

£ 70 M

Deal Value

neurogene inc

HQ - United States

Biotechnology

16 Dec 2020

Investment Date

£ 85 M

Deal Value

visen pharmaceuticals

HQ - China

Pharmaceuticals

11 Jan 2021

Investment Date

£ 111 M

Deal Value

centessa pharmaceuticals

HQ - United Kingdom

Pharmaceuticals

16 Feb 2021

Investment Date

£ 179 M

Deal Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy